A Phase 3, Randomized, Open-label Study Of Lorlatinib (Pf-06463922) Monotherapy Versus Crizotinib Monotherapy In The First-line Treatment Of Patients With Advanced Alk-positive Non-small Cell Lung Cancer
Phase of Trial: Phase III
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Lorlatinib (Primary) ; Crizotinib
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms CROWN
- Sponsors Pfizer
- 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
- 08 Sep 2017 According to the Trial design presented at the 42nd European Society for Medical Oncology Congress,the first patient was screened on April 14, 2017.
- 24 Jul 2017 Planned End Date changed from 12 Aug 2023 to 23 Oct 2023.